Protein Tyrosine Kinases:Their Roles and Their Targeting in Leukemia
Protein tyrosine kinases superfamily definition A large group of enzymes that speeding up protein phosphorylation and controlling multiple signaling incidents are titled as Protein tyrosine kinases, which represents a complicated system and is wrapped up by of 518 members. Based on their ability to phosphorylate either tyrosine or serine and threonine residues, they are classified into two main […]
Disease modifying therapies (DMTs)
Quick Review Over Disease Modifying Therapies (DMTs) For Multiple Sclerosis Introduction: Multiple sclerosis (MS) is an immune-mediated inflammatory demyelinating disease of the CNS. Although there is no curable options for MS, a number of medications also called, disease modifying therapies, or DMTs, have been approved to treat MS. Permanent damage to the central nervous system can […]
Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of non-small cell lung cancer: a patent review (2014-present) One of the most common and deadliest disease on record is lung cancer. According to estimates with increasing incidence each year, about 85% of lung cancer cases are non-small cell lung cancer type, and about […]
Type 2 Diabetes Mellitus
Overview of Type 2 Diabetes Mellitus Type 2 diabetes mellitus is the most common type of diabetes, in which the blood glucose, is too high. This chronic condition may lead to disorders of the circulatory, nervous and immune systems, and affects your everyday life. In type 2 diabetes there are mainly 2 associated problems; body […]
Parsian Pharama Review of CDK4/6 Inhibitors Citing to the Recent Articles
Parsian pharama review of CDK4-6 inhibitors citing to the recent articles One of the most common cancers among women is Breast cancer. Sometimes the average risk of developing breast cancer in a woman in the United States in her lifespan is about 13%. More than 70% of breast cancer cases are Hormone receptor–positive (HR+) types, […]
US FDA Approved Empagliflozin
The U.S. FDA Approved Empagliflozin for Wider Range of Patients with Heart Failure Abstracts: On February 24, 2022, The U.S. FDA approved an expanded indication for empagliflozin which is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, to reduce the risk of Cardiovascular (CV) death and Heart failure (HF) hospitalization in adults with HF with reduced or […]
Breaking news; U.S FDA advisory panel narrowly endorses Molnupiravir
Breaking news; U.S FDA advisory panel narrowly endorses Molnupiravir U.S FDA advisory panel narrowly endorses Molnupiravir, for Mild to Moderate COVID-19 in High Risk patients, despite reduced efficacy and safety questions . A Food and Drug Administration advisory panel on Tuesday narrowly endorsed the use of Merck and Ridgeback’s at-home Covid treatment pill, despite questions about […]
Aromatase Inhibitors
Parsian pharma review of aromatase inhibitors (AIs) citing to the recent articles regard this subject: Key points that led Parsian pharma to choose Letrozole over other aromatase inhibitors Cell growth in breast cancer is essentially derived by estrogen in both premenopausal and postmenopausal women. Most of the breast cancer cases are among postmenopausal women, […]
Some Tips for Patients who are Taking a CDK4/6 Inhibitor
Some Tips for Patients who are Taking a CDK4/6 Inhibitor CDK4/6 inhibitors are pills taken orally and mostly they are prescribed along with hormonal therapy. If you are taking a CDK4/6 inhibitor, in this article Parsian pharma have some recommendations that can help things go more easily. Create a system for organizing your medications Ask your […]
A Quick Review Over Leukemia
What is leukemia? Leukemia is a cancer of the blood-forming tissues, like the lymphatic system and the bone marrow. There are several broad categories of blood cells, including white blood cells (WBCs), platelets and red blood cells (RBCs). Mostly, leukemia refers to cancers of the WBCs. It is characterized by a large rise in the numbers […]